Previous Article | Next Article 
Antimicrob Agents Chemother. 1991 December; 35(12): 2505-2508
Effect of protein binding of daptomycin on MIC and antibacterial activity.
B L Lee,
M Sachdeva and
H F Chambers
Department of Medicine, University of California, San Francisco General Hospital 94110.
ABSTRACT
A higher rate of clinical failures in patients treated with daptomycin (2 mg/kg of body weight, given once daily) compared with rates in patients treated with conventional regimens caused early termination of this comparative clinical trial. One explanation for these failures could be that daptomycin is highly protein bound and that the concentration of the unbound active drug is too low for antibacterial activity. To assess this explanation, we studied the binding of daptomycin to proteins by using an ultrafiltration method. pH (7.0 to 7.4), temperature (25 or 37 degrees C), or daily freezing and thawing over 2 months had no effect on binding of daptomycin to proteins. We found that daptomycin was bound to albumin (90%) at 4 g/100 ml. Binding of daptomycin was not concentration dependent (2.5 to 80 micrograms/ml). In human serum samples spiked with daptomycin, average binding was 94% +/- 2.4%. In 6 subjects given an intravenous infusion of daptomycin (3 mg/kg), average binding was 90% +/- 2.1%. Susceptibility studies showed that a concentration in serum 20 times the unbound concentration was needed to equal the MIC of the total drug. These results indicate that daptomycin is highly bound (90 to 94%) to albumin and that clinical failure to daptomycin can in part be explained by the low concentration of the unbound drug.
Antimicrob Agents Chemother. 1991 December; 35(12): 2505-2508
This article has been cited by other articles:
-
Schmidt, S., Rock, K., Sahre, M., Burkhardt, O., Brunner, M., Lobmeyer, M. T., Derendorf, H.
(2008). Effect of Protein Binding on the Pharmacological Activity of Highly Bound Antibiotics. Antimicrob. Agents Chemother.
52: 3994-4000
[Abstract]
[Full Text]
-
Schwartz, B. S, Ngo, P. D, Guglielmo, B J.
(2008). Daptomycin Treatment Failure for Vancomycin-Resistant Enterococcus faecium Infective Endocarditis: Impact of Protein Binding?. The Annals of Pharmacotherapy
42: 289-290
[Full Text]
-
Rose, W. E., Rybak, M. J., Kaatz, G. W.
(2007). Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother
60: 334-340
[Abstract]
[Full Text]
-
Vouillamoz, J., Moreillon, P., Giddey, M., Entenza, J. M.
(2006). Efficacy of daptomycin in the treatment of experimental endocarditis due to susceptible and multidrug-resistant enterococci. J Antimicrob Chemother
58: 1208-1214
[Abstract]
[Full Text]
-
French, G. L.
(2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother
58: 1107-1117
[Abstract]
[Full Text]
-
Schriever, C. A., Fernandez, C., Rodvold, K. A., Danziger, L. H.
(2005). Daptomycin: A novel cyclic lipopeptide antimicrobial. Am J Health Syst Pharm
62: 1145-1158
[Abstract]
[Full Text]
-
Huang, V., Rybak, M. J.
(2005). Pharmacodynamics of Cefepime Alone and in Combination with Various Antimicrobials against Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model. Antimicrob. Agents Chemother.
49: 302-308
[Abstract]
[Full Text]
-
Cha, R., Brown, W. J., Rybak, M. J.
(2003). Bactericidal Activities of Daptomycin, Quinupristin-Dalfopristin, and Linezolid against Vancomycin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother.
47: 3960-3963
[Abstract]
[Full Text]
-
Cha, R., Grucz, R. G. Jr., Rybak, M. J.
(2003). Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms. Antimicrob. Agents Chemother.
47: 1598-1603
[Abstract]
[Full Text]
-
Sakoulas, G., Eliopoulos, G. M., Alder, J., Eliopoulos, C. T.
(2003). Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcusaureus. Antimicrob. Agents Chemother.
47: 1714-1718
[Abstract]
[Full Text]
-
Fuchs, P. C., Barry, A. L., Brown, S. D.
(2002). In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother
49: 467-470
[Abstract]
[Full Text]
-
Louie, A., Kaw, P., Liu, W., Jumbe, N., Miller, M. H., Drusano, G. L.
(2001). Pharmacodynamics of Daptomycin in a Murine Thigh Model of Staphylococcus aureus Infection. Antimicrob. Agents Chemother.
45: 845-851
[Abstract]
[Full Text]
-
Akins, R. L., Rybak, M. J.
(2001). Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus faecium, and Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother.
45: 454-459
[Abstract]
[Full Text]
-
Oleson, F. B. Jr., Berman, C. L., Kirkpatrick, J. B., Regan, K. S., Lai, J.-J., Tally, F. P.
(2000). Once-Daily Dosing in Dogs Optimizes Daptomycin Safety. Antimicrob. Agents Chemother.
44: 2948-2953
[Abstract]
[Full Text]
-
Cetinkaya, Y., Falk, P., Mayhall, C. G.
(2000). Vancomycin-Resistant Enterococci. Clin. Microbiol. Rev.
13: 686-707
[Abstract]
[Full Text]
-
Tally, F. P., DeBruin, M. F.
(2000). Development of daptomycin for Gram-positive infections. J Antimicrob Chemother
46: 523-526
[Full Text]
-
Akins, R. L., Rybak, M. J.
(2000). In Vitro Activities of Daptomycin, Arbekacin, Vancomycin, and Gentamicin Alone and/or in Combination against Glycopeptide Intermediate-Resistant Staphylococcus aureus in an Infection Model. Antimicrob. Agents Chemother.
44: 1925-1929
[Abstract]
[Full Text]
Copyright © 1991 by the American Society for Microbiology. All rights reserved.